•   
  •   

Health & Fitness J&J coronavirus vaccine can resume in US, CDC advisory panel recommends

06:05  24 april  2021
06:05  24 april  2021 Source:   livescience.com

Quick guide: COVID-19 vaccines in use and how they work

  Quick guide: COVID-19 vaccines in use and how they work Here's a guide to the vaccines being used in different countries.Dozens of coronavirus vaccines entered clinical trials during 2020, and now, a handful have been authorized for emergency use in various countries — meaning the shots can be administered to the public while their developers continue to collect data on their safety and efficacy. Should they meet all the necessary criteria, these vaccines could be fully approved in the future, and in some places, they already have been.

A CDC advisory panel voted to recommend that the U . S . resume administering the Johnson & Johnson vaccine for people 18 years of age and older. This comes after an 11-day pause in administering the vaccine prompted by reports of extremely rare, but severe, blood clots that developed post- vaccination in a handful of people. During an Advisory Committee on Immunization Practices meeting held on Friday (April 23), the panel voted 10 to 4 to resume Johnson & Johnson vaccination among all age groups, but they recommended that a warning label be added to include the possibility

A CDC advisory panel on Friday recommended the U . S . resume using the Johnson and Johnson Covid-19 vaccine . The Food and Drug Administration and CDC on April 13 asked states to temporarily halt using J & J 's vaccine "out of an abundance of caution" following reports of the rare blood clots. Within hours of the warning, more than a dozen states as well as some national pharmacies halted inoculations with J & J 's vaccine , some replacing scheduled appointments with either the Pfizer or Moderna vaccine .

A Centers for Disease Control and Prevention (CDC) advisory panel voted to recommend that the U.S. resume administering the Johnson & Johnson vaccine for people 18 years of age and older. This comes after an 11-day pause in administering the vaccine prompted by reports of extremely rare, but severe, blood clots that developed post-vaccination in a handful of people.

A vaccine syringe in front of a Johnson and Johnson logo. © Provided by Live Science A vaccine syringe in front of a Johnson and Johnson logo.

During an Advisory Committee on Immunization Practices meeting held on Friday (April 23), the panel voted 10 to 4 to resume Johnson & Johnson vaccination among all age groups, but they recommended that a warning label be added to include the possibility that the vaccine may increase the risk of such blood clots.

THOUSANDS of Americans have had bad reactions to coronavirus vaccines

  THOUSANDS of Americans have had bad reactions to coronavirus vaccines Of more than 13.7 million coronavirus vaccine doses administered between mid-December 2020 and mid-January 2021, there were 6,994 reports of adverse events submitted to the CDC's reporting system.Nearly 7,000 people had an 'adverse event' after being given either the Pfizer-BioNTech or the Moderna shot, the Centers for Disease Control and Prevention (CDC) revealed on Friday.

Johnson & Johnson’s coronavirus vaccine rollout should resume in the US , the CDC and FDA said, but the shot will come with a warning about rare side-effects after blood clotting in recipients prompted a pause on vaccinations . Earlier in the day, the Advisory Committee on Immunization Practices voted 10 to 4 to recommend lifting the 11-day hiatus on Friday, with one member abstaining over a potential conflict of interest. While the panel said the J & J shot’s benefits outweigh its risks, it nonetheless suggested attaching a notice to the vaccine about increased chances for a rare, but dangerous, form

A member of a key CDC advisory panel told CNBC on Friday morning that he expects the U . S . pause on Johnson & Johnson's one-dose coronavirus vaccine to eventually be lifted. I also appreciate the importance of acting swiftly, in collaboration with the FDA, once we hear from ACIP," Walensky added. Given the urgency of the coronavirus pandemic, some people have criticized the decision to halt the J & J Covid vaccine — which only requires one dose for full immunity protection — while the investigation into blood clots took place.

Now, the CDC will decide whether to accept the recommendation, according to NBC News.

Related: Quick guide: COVID-19 vaccines in use and how they work

The CDC and the Food and Drug Administration (FDA) had recommended a pause in Johnson & Johnson vaccinations in the U.S. on April 13 to investigate six cases of the rare clotting disorder recently coined as "thrombosis with thrombocytopenia syndrome" (TTS). In the week and a half since, officials have confirmed another nine cases, bringing the total to 15.

That's only a tiny proportion of the more than 8 million people who have been given the Johnson & Johnson vaccine in the U.S. so far, according to the CDC.  Of those cases, 13 were women between the ages of 18 and 49, and two were women who were 50 years of age or older. That means for women between the ages of 18 and 49, the risk of developing such blood clots appears to be 7 per million, and the risk for women who are 50 years of age or older appears to be 0.9 per million. There are another 10 cases that are currently under review, which may include males, according to the presenters at the ACIP.

Covid vaccine side effects: CDC warns of three new 'common side effects' to be aware of

  Covid vaccine side effects: CDC warns of three new 'common side effects' to be aware of ALL VACCINES come with the risk of side effects, but with the Covid vaccines being so new, the full extent of reactions is still being determined. The Centers for Disease Control and Prevention (CDC) has just updated its list of Covid vaccine side effects, adding three conditions that may occur following the jab.The CDC updated its vaccine guidance on March 5 and listed muscle pain among "common side effects".

The CDC panel reviewed evidence from 15 people who suffered blood clots after receiving the JNJ jab, out of a total of 8 million Americans injected. Of these, three died, while seven remain hospitalized and five were discharged. All 15 cases of clotting were observed in women, with 13 under the age of 50 Prior to Friday’s vote, the committee debated whether to recommend against the use of J & J ’s vaccine or endorse it with U . S . regulators enforcing a warning label. The committee also considered limiting the vaccine ’s use based on age or other risk factors. Rare blood clots with low platelets are occurring at a

A group of advisors to the CDC is set to meet on Johnson & Johnson's coronavirus vaccine . The group will review rare cases of blood clots that occurred after vaccination in individuals with low platelet counts. CNBC's Meg Tirrell reports.

Three of those patients died and seven remain hospitalized. There wasn't a clear trend in risk factors among those who developed TTS other than being younger and female; seven were obese; two had hypothyroidism; two were using oral contraceptives; and two had high blood pressure.


Gallery: 10 ways COVID-19 changed the world (Live Science)

The group discussed a spectrum of options for how to proceed with Johnson & Johnson vaccinations in the U.S., including continuing the recommendation that the vaccine can be given to everyone 18 years of age and older and the option of setting an age limit since the cases of TTS appear more common in younger populations.

CDC scientist Dr. Sara Oliver presented risk/benefit modeling on these various scenarios. Their modeling suggests that continuing the Johnson & Johnson vaccine for everyone ages 18 and older may cause 26 to 45 cases of TTS but would prevent 600 to 1,400 deaths and 800 to 3,500 intensive care unit (ICU) admissions. It would also allow flexibility and ability to vaccinate harder-to-reach populations.

If they recommend the vaccine just for people 50 years of age or older, it would likely lead to two or three cases of TTS and prevent 300 to 1,000 ICU admissions and 40 to 250 deaths.

The experts did not see a good reason to stop using the Johnson & Johnson vaccine completely or limit its use to certain age groups. The discussion mainly centered around whether to recommend the Johnson & Johnson vaccine to everyone ages 18 and older or recommend it with a warning that women under the age of 50 "should be aware" of the increased risk of TTS and have an option of choosing another COVID-19 vaccine.

The Johnson & Johnson vaccine is an adenovirus-based vaccine that's similar to the one developed by AstraZeneca and the University of Oxford. The AstraZeneca vaccine has also prompted cases of TTS and was paused across many countries while being investigated; most countries have resumed administering the AstraZeneca shot but with various age restrictions and guidelines, Live Science previously reported.

Of the more than 214 million doses of mRNA vaccines — those made by Moderna and Pfizer — administered in the U.S., there have not been any reports of TTS.

On Tuesday (April 20), the European Medicines Agency concluded that there is a possible link between the J&J vaccine and rare cases of these blood clots and that a warning should be added to the product information; Johnson & Johnson announced the same day that it will resume shipment of its vaccine to the European Union, Norway and Iceland.

Originally published on Live Science.

US could see lowest death rate since pandemic's early days by JUNE .
B.1.1.7, the coronavirus variant first detected in the U.K., is now causing two out of every three COVID-19 cases in the U.S., according to the CDC. This variant is more contagious than older strains.New COVID-19 deaths may fall as low as 1,500 in a week by early June, according to new predictions from the Centers for Disease Control and Prevention (CDC).

usr: 1
This is interesting!